Noticias de ANTX_US

Mercado

Noticias del mercado

Últimas noticias sobre ANTX_US — 125 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ANTX_US ✕ 125 resultados
31/08/2026 ANTX_US — www.dars.gov.et
ANTX Q2 2026 Earnings: Narrower-than-Expected Loss of $0.18 per Share as Clinical Pipeline Advances - EPS Miss Report
31/08/2026 ANTX_US — BioSpace
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
31/08/2026 ANTX_US — Business Wire
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
30/08/2026 ANTX_US — Value Research
AN2 Therapeutics Inc (ANTX) Shareholding Pattern – Promoters, FIIs & DIIs
30/08/2026 ANTX_US — StocksToTrade
AN2 Therapeutics Inc. (ANTX) Stock Price | Live Quotes & Charts | NASDAQ

Get latest AN2 Therapeutics Inc. (ANTX) stock price, news, and charts. Access real-time quotes and historical data with interactive charts and tools to make informed trading decisions.

24/08/2026 ANTX_US — BioSpace
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
24/08/2026 ANTX_US — Investing.com
AN2 Therapeutics names Cameron Trenor as chief medical officer By Investing.com
24/08/2026 ANTX_US — Investing.com
AN2 Therapeutics names Cameron Trenor as chief medical officer By Investing.com
24/08/2026 ANTX_US — Investing.com
AN2 Therapeutics names Cameron Trenor as chief medical officer By Investing.com
24/08/2026 ANTX_US — Yahoo Finance
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
24/08/2026 ANTX_US — Investing.com
AN2 Therapeutics names Cameron Trenor as chief medical officer By Investing.com
24/08/2026 ANTX_US — Business Wire
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
24/08/2026 ANTX_US — Contract Pharma
AN2 Therapeutics Names Dr. Cameron Trenor as Chief Medical Officer

AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Cameron Trenor, M.D., as Chief Medical Officer.

24/08/2026 ANTX_US — Investing.com
AN2 Therapeutics names Cameron Trenor as chief medical officer
23/08/2026 ANTX_US — vinanet.vn
AN2 (ANTX) Shares: Moves 0.35% Up to $5.81 in Latest Trading; Price Levels: Support at $5.52 and Resistance at $6.10 Frame the Range in the Available Record - Volume Profile
19/08/2026 ANTX_US — Investing.com
An2 Therapeutics director Robin Readnour sells $212,701 in common stock
19/08/2026 ANTX_US — Investing.com ES ← EN
El director de An2 Therapeutics, Robin Readnour, vende 212.701 dólares en acciones ordinarias Por Investing.com

An2 Therapeutics director Robin Readnour sells $212,701 in common stock By Investing.com

19/08/2026 ANTX_US — Vinanet
AN2 (ANTX) Results at a Glance: EPS Misses Its Estimate under the Current Snapshot; After Earnings
19/08/2026 ANTX_US — careplusvn.com
AN2 (ANTX) Results at a Glance: EPS Misses Its Estimate under the Current Snapshot; After Earnings
19/08/2026 ANTX_US — Investing.com
An2 Therapeutics director Robin Readnour sells $212,701 in common stock

Página 5 de 7